✦ LIBER ✦

Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice

✍ Scribed by Ravaud, A; Bedane, C; Geoffrois, L; Lesimple, T; Delaunay, M

Book ID: 110002382
Publisher: Nature Publishing Group
Year: 1999
Tongue: English
Weight: 49 KB
Volume: 80
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6690595

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Toxicity and feasibility of adjuvant hig

Toxicity and feasibility of adjuvant high dose interferon alpha-2b in patients with melanoma

✍ C. Bédane; A. Ravaud; L. Geoffrois; t. Lesimple; M. Delaunay; J.M. Bonnetblanc 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

The feasibility of adjuvant interferon α

The feasibility of adjuvant interferon α-2b in children with high-risk melanoma

✍ Fariba Navid; Wayne L. Furman; Martin Fleming; Bhaskar N. Rao; Sandra Kovach; Ca 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract ## BACKGROUND It has been shown that induction high‐dose interferon α‐2b (IFN‐α‐2b) followed by maintenance therapy improves recurrence‐free survival in adults with high‐risk, resected melanoma. In this study, the feasibility and toxicity of this regimen were evaluated in newly diagnos

7022 POSTER High dose interferon alpha 2

7022 POSTER High dose interferon alpha 2b as adjuvant therapy in high-risk resected malignant melanoma: 10 year experience of patients treated in Northern Ireland

✍ Jain, S.K.; Mulholland, L.; McCourt, C.; Connolly, D.; Khan, E.E.; Wilson, J.; B 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Significant differences in the decision

Significant differences in the decision making process exist between melanoma patients who accept or decline high-dose adjuvant interferon-alpha-2B therapy

✍ Stacey A Freedman; Tracy Bialy; Liana Abramova; Suephy Chen 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Autoimmunity as a prognostic factor in m

Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha

✍ Imke Satzger; Andre Meier; Florian Schenck; Alexander Kapp; Axel Hauschild; Ralf 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 114 KB

## Abstract Interferon alpha is used for the adjuvant treatment of malignant melanoma at different dosages (high‐, intermediate‐, low‐dose therapy). Only a minority of patients might benefit from this therapy, and markers to identify such patients are missing. A recent study suggested that melanoma

Interferon Alfa-2b or Not 2b? Significan

Interferon Alfa-2b or Not 2b? Significant Differences Exist in the Decision-Making Process between Melanoma Patients Who Accept or Decline High-Dose Adjuvant Interferon Alfa-2b Treatment

✍ TRACY B. BRAMLETTE; DAVID H. LAWSON; CARL V. WASHINGTON; EMIR VELEDAR; BARRY R. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB